New hope for MOGAD patients: drug aims to stop relapses

NCT ID NCT06452537

Ongoing Disease control Sponsor: Tianjin Medical University General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug tocilizumab can safely prevent or delay relapses in people with MOGAD, a rare autoimmune disease that attacks the nervous system. About 102 participants aged 12 and older who have had at least one relapse in the past year will receive either tocilizumab or a placebo. The main goal is to see if the drug reduces the number of relapses over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelin oligodendrocyte glycoprotein antibody-associated disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE

Contacts and locations

Locations

Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, 221006, China
Anhui Provincial Hospital

Hefei, Anhui, 230001, China
Beijing Tiantan Hospital, Capital Medical University

Beijing, 100000, China
Children's Hospital of Soochow University

Suzhou, Jiangsu, 215025, China
China-Japan Friendship Hospital

Beijing, 100000, China
Chinese PLA General Hospital

Beijing, 100000, China
First Hospital of Shanxi Medical University

Taiyuan, Shanxi, 030000, China
General Hospital of Ningxia Medical University

Yinchuan, Ningxia, 751705, China
Hebei Children's Hospital

Shijiazhuang, Hebei, 050000, China
Huashan Hospital, Fudan University

Shanghai, 200000, China
Ordos Central Hospital

Ordos, Inner Mongolia, 017000, China
People's Hospital of Xinjiang Uygur Autonomous Region

Ürümqi, Xinjiang Uygur Autonomous Region, 830001, China
The First Affiliated Hospital of Tsinghua University

Beijing, 100000, China
The First Affiliated Hospital of Zhengzhou University

Zhenzhou, Henan, China
The Second Affiliated Hospital of Harbin Medical University

Harbin, Heilongjiang, 150086, China
The Second Hospital of Hebei Medical University

Shijiazhuang, Hebei, 050000, China
The Second Hospital of Lanzhou University

Lanzhou, Gansu, 73000, China
The Third Affiliated Hospital of Soochow University

Changzhou, Jiangsu, 213000, China
Tianjin Children's Hospital

Tianjin, 30052, China
Tianjin Huanhu Hospital

Tianjin, 300052, China
Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, 300052, China
XuanWu Hospital Capital Medical University

Beijing, 100000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.